GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redwood Pharma AB (OSTO:REDW) » Definitions » EV-to-FCF

Redwood Pharma AB (OSTO:REDW) EV-to-FCF : -0.16 (As of May. 27, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Redwood Pharma AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Redwood Pharma AB's Enterprise Value is kr1.78 Mil. Redwood Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was kr-11.47 Mil. Therefore, Redwood Pharma AB's EV-to-FCF for today is -0.16.

The historical rank and industry rank for Redwood Pharma AB's EV-to-FCF or its related term are showing as below:

OSTO:REDW' s EV-to-FCF Range Over the Past 10 Years
Min: -2.56   Med: 0   Max: 0.33
Current: -0.16

During the past 8 years, the highest EV-to-FCF of Redwood Pharma AB was 0.33. The lowest was -2.56. And the median was 0.00.

OSTO:REDW's EV-to-FCF is ranked worse than
100% of 369 companies
in the Biotechnology industry
Industry Median: 8.9 vs OSTO:REDW: -0.16

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Redwood Pharma AB's stock price is kr0.812. Redwood Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-6.582. Therefore, Redwood Pharma AB's PE Ratio for today is At Loss.


Redwood Pharma AB EV-to-FCF Historical Data

The historical data trend for Redwood Pharma AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redwood Pharma AB EV-to-FCF Chart

Redwood Pharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial -3.43 -8.34 -9.68 -1.68 -0.51

Redwood Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -1.14 -2.56 -0.93 -0.20

Competitive Comparison of Redwood Pharma AB's EV-to-FCF

For the Biotechnology subindustry, Redwood Pharma AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redwood Pharma AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Redwood Pharma AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Redwood Pharma AB's EV-to-FCF falls into.



Redwood Pharma AB EV-to-FCF Calculation

Redwood Pharma AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1.781/-11.467
=-0.16

Redwood Pharma AB's current Enterprise Value is kr1.78 Mil.
Redwood Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-11.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redwood Pharma AB  (OSTO:REDW) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Redwood Pharma AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.812/-6.582
=At Loss

Redwood Pharma AB's share price for today is kr0.812.
Redwood Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-6.582.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Redwood Pharma AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Redwood Pharma AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Redwood Pharma AB (OSTO:REDW) Business Description

Traded in Other Exchanges
Address
Ringvagen 100E, 9th Floor, Stockholm, SWE, 118 60
Redwood Pharma AB is engaged in developing new ophthalmic pharmaceutical therapies for unmet market needs. Its development product is a new therapy to treat chronic Dry Eye Disease (DED) in post-menopausal women.

Redwood Pharma AB (OSTO:REDW) Headlines

No Headlines